BNP Paribas Financial Markets Makes New $27,000 Investment in Alumis Inc. (NASDAQ:ALMS)

BNP Paribas Financial Markets purchased a new stake in Alumis Inc. (NASDAQ:ALMS) during the third quarter, Holdings Channel.com reports. The firm purchased 2,567 shares of the company’s stock, valued at approximately $27,000.

Other large investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. purchased a new stake in Alumis during the 3rd quarter worth approximately $1,160,000. Towerview LLC raised its position in shares of Alumis by 22.6% in the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after acquiring an additional 70,000 shares during the period. Maven Securities LTD purchased a new position in Alumis during the second quarter worth approximately $332,000. Millennium Management LLC acquired a new position in Alumis during the second quarter worth $3,376,000. Finally, Yu Fan purchased a new position in shares of Alumis in the second quarter valued at approximately $10,502,000.

Analysts Set New Price Targets

A number of research firms have weighed in on ALMS. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of Alumis in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Finally, Robert W. Baird initiated coverage on Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price on the stock. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Alumis presently has an average rating of “Buy” and a consensus price target of $26.83.

Alumis Stock Up 2.2 %

ALMS stock opened at $8.82 on Friday. Alumis Inc. has a 12 month low of $7.66 and a 12 month high of $13.53. The firm has a fifty day simple moving average of $10.21.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.